14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MLTX vs INVA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas INVA carries 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin).
Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile INVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs INVA. Trailing 12-month operating profitability (MLTX 0.0% vs INVA 39.5%) and valuation multiples (MLTX N/M vs INVA 8.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
INVA Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 39.5% operating margin.
OpEx & R&D Reinvestment37.5% of Rev ($164M)
90D Engineering Disclosures0 Published
Investor FAQ MLTX vs INVA Key Questions & Quantitative Answers
As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas INVA carries 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin). Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile INVA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INVA leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INVA at -1.6% YoY revenue growth and +590.4% YoY earnings growth on $438M TTM revenue (77.0% gross margin, 39.5% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $438M for INVA. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus 37.5% of Rev ($164M) (0 disclosures) for INVA.
INVA screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas INVA trades at 8.8x Forward P/E, 8.1x Trailing P/E, 2.82x PEG, and 2.4x EV/Revenue (41.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus INVA (18.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, INVA carries 23.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.